Fuzhou

Futó vizsgálatok

• Toboroz

  A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

  NCT07686120· 3. fázis· Forrás

• Toboroz

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· 3. fázis· Forrás

• Toboroz

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· 3. fázis· Forrás

• Toboroz

  A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

  NCT07751848· 3. fázis· Forrás

• Toboroz

  Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

  NCT07596784· 3. fázis· Forrás

• Toboroz

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· 3. fázis· Forrás

• Toboroz

  Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

  NCT07593248· Forrás

• Toboroz

  A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

  NCT07613424· Forrás

• Toboroz

  Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

  NCT07279935· 4. fázis· Forrás

• Toboroz

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· 3. fázis· Forrás

• Fut, nem toboroz

  Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

  NCT07338942· Forrás

• Toboroz

  Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

  NCT07295821· 2. fázis· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· Forrás

• Toboroz

  Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

  NCT07363642· 3. fázis· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· Forrás

• Toboroz

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· 3. fázis· Forrás

• Toboroz

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· 1/2. fázis· Forrás

• Toboroz

  Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

  NCT07161388· Forrás

• Toboroz

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· 3. fázis· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· Forrás

• Toboroz

  A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  NCT07069712· 2. fázis· Forrás

• Fut, nem toboroz

  Hyperkalemia Quality Improvement Program (HK-QIP) Study

  NCT06884267· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· Forrás

• Toboroz

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· 3. fázis· Forrás

• Toboroz

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· 3. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· 3. fázis· Forrás

• Fut, nem toboroz

  A Study in Patients With Myasthenia Gravis in China

  NCT06700616· Forrás

• Fut, nem toboroz

  A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

  NCT06610526· 4. fázis· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· Forrás

• Toboroz

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· 3. fázis· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Forrás

• Toboroz

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· 3. fázis· Forrás

• Fut, nem toboroz

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· 3. fázis· Forrás

• Toboroz

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· 3. fázis· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· Forrás

• Toboroz

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

  NCT05984277· 3. fázis· Forrás

• Toboroz

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

  NCT05775159· 2. fázis· Forrás

• Fut, nem toboroz

  Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

  NCT05557838· 3. fázis· Forrás

• Fut, nem toboroz

  Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

  NCT05546866· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· 3. fázis· Forrás

• Fut, nem toboroz

  Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

  NCT05556096· 3. fázis· Forrás

• Fut, nem toboroz

  Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  NCT05261399· 3. fázis· Forrás

• Fut, nem toboroz

  Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

  NCT05457257· 4. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák11 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Máj- és epeúti rák3 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)2 toboroz
• Méhtestrák2 toboroz
• Petefészekrák2 toboroz
• Prosztatarák2 toboroz
• Amiloidózis1 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Follikuláris limfóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Hólyagrák1 toboroz
• Lupus (SLE)1 toboroz
• Magas vérnyomás1 toboroz
• Méhnyakrák1 toboroz
• Myasthenia gravis1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· 2. fázis· Forrás

• Toboroz

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· 2. fázis· Forrás

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· Forrás

• Lezárult

  Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

  NCT06764160· 3. fázis· Forrás

• Lezárult

  An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

  NCT06605885· Forrás

• Lezárult

  Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

  NCT06590740· 4. fázis· Forrás

• Toboroz

  Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  NCT06535607· 2. fázis· Forrás

• Lezárult

  A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD

  NCT06172777· Forrás

• Leállították

  Non-alcoholic Steatohepatitis Registry Platform Study

  NCT06123858· Forrás

• Lezárult

  A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

  NCT05924880· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05809934· 2. fázis· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Forrás

• Lezárult

  Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

  NCT05219162· 4. fázis· Forrás

• Lezárult

  Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

  NCT04989816· 2. fázis· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· 3. fázis· Forrás

• Lezárult

  Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection

  NCT04419233· Forrás

• Lezárult

  Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  NCT03927157· 3. fázis· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· Forrás

• Lezárult

  Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

  NCT02442349· 2. fázis· Forrás

• Lezárult

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· 3. fázis· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· Forrás

• Lezárult

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· 3. fázis· Forrás